For patients with advanced non-small cell lung cancer, targeted therapy based on EGFR-TKI drugs has good efficacy and is increasingly adopted by the majority of patients. However, some patients who take these drugs, especially troche, develop more serious rash, which is itchy and painful and affects their life, and they are more concerned about the choice of treatment, which is very disturbing. With reference to the literature and combined with clinical experience, here is a relevant introduction, hoping to help patients. Itchy and painful rash and pustules are common skin toxic reactions to EGFR-TKI drugs. The incidence is reported to be about 50%-80%, manifesting as papular and pustular lesions on the face and trunk, accompanied by dry and itchy, or painful, perinephritis, nail fracture, hair loss, eyelash and facial hair growth, etc. It is rarely life-threatening, but can seriously affect the quality of life. Most skin toxic reactions occur within 2 weeks of taking Troche, with a peak at about 3-5 weeks. Whether to continue taking the drug, or to reduce the dose, or to stop treating the skin lesions is a concern for many of these patients. The degree of skin lesions is judged clinically according to the National Cancer Institute Common Toxic Reaction Criteria (NCI-CTCAE 3.0), and with reference to the consensus of some European and American experts, the following is recommended: degree 1: lesions <10% body surface area (BSA), papules, pustules, asymptomatic erythema. No need to adjust the dose of medication, can only be used as a preventive treatment for lesions. Grade 2: 2A lesions <50% BSA, papules; 2B lesions <50% BSA, papules with pustules, moderate symptoms, no restriction of daily life. This stage also does not require any adjustment of the dosage, but requires topical or systemic antibiotics. Grade 3: 3A lesions >50% BSA, papules; 3B lesions >50% BSA, papules with pustules, severe symptoms, interference with daily life. If it occurs after the first dose, it is recommended to postpone (<21 days) the use, if improvement to maintain the original dose, no improvement to terminate treatment; the second occurrence, it is recommended to postpone (<21 days) the use until the lesions improve <2 degrees, if there is improvement to reduce the dose appropriately, no improvement to terminate treatment; the third occurrence, it is recommended to postpone (<21 days) the use until the lesions improve <2 degrees, if there is improvement to reduce the dose again, no Termination of treatment without improvement. Topical or systemic application of antibiotics or even glucocorticoids is required. Grade 4: Extensive skin toxicity with severe symptoms requiring urgent treatment. Terminate EGFR-TKI drug therapy immediately and treat for skin toxicity. Of course, the treatment choice process needs to pay more attention to the patient's own feelings, reflecting the patient-centered, doctor-assisted patient treatment model.